ALIMERA SCIENCES INC
ALIMERA SCIENCES INC (ALIM): 2 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.1 months
D/E 2.88 · 0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for ALIMERA SCIENCES INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$10.9M
Quarterly Burn
$23.2M
Runway
3.1 mo
Revenue
$27.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in ALIMERA SCIENCES INC's pipeline?
ALIMERA SCIENCES INC (ALIM) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ALIMERA SCIENCES INC's lead drug candidate?
ALIMERA SCIENCES INC's most advanced tracked candidate is iluvien (Approved) for Non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
What is ALIMERA SCIENCES INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ALIMERA SCIENCES INC has approximately 3.1 months of cash runway.
Get the full picture on ALIMERA SCIENCES INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.